Unlock instant, AI-driven research and patent intelligence for your innovation.

Interferon alpha1b mutant and fusion protein containing interferon alpha1b and human serum albumin

A technology of human serum albumin and interferon α, which is applied in the field of interferon α1b mutants and their fusion proteins with human serum albumin, which can solve the problems of decreased biological activity of proteins

Active Publication Date: 2015-04-01
BEIJING TRI PRIME GENE PHARMA CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the main disadvantage of the fusion protein technology, especially the fusion technology of the target protein and human serum albumin, is that the biological activity of the protein after fusion decreases significantly, and the extension of the half-life in vivo needs to be further improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Interferon alpha1b mutant and fusion protein containing interferon alpha1b and human serum albumin
  • Interferon alpha1b mutant and fusion protein containing interferon alpha1b and human serum albumin
  • Interferon alpha1b mutant and fusion protein containing interferon alpha1b and human serum albumin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: Construction of Engineering Bacteria Expressing Interferon α1b164 Serine Mutant and Confirmation of Expression Sequence

[0048] Extract the plasmid pET23b / IFN plasmid of interferon α1b as a template, and the primers of the reaction system are:

[0049] P1: 5'-TGCAGGAACGTCTGCGTAGTAAAGAATAACGAATTC-3',

[0050] P2: 5'-GAATTCGTTATTCTTACTACGCAGACGTTCCTGCA-3',

[0051] The reaction conditions were: pre-denaturation at 94°C for 5 minutes, denaturation at 94°C for 1 minute, annealing at 53°C for 1 minute, extension at 72°C for 90 seconds, 30 cycles, and extension at 72°C for 5 minutes.

[0052] The PCR product was analyzed by agarose electrophoresis, and a DNA fragment of about 720bp was selected, digested with Nde I / EcoRI double enzymes, and the target DNA fragment of about 500bp was recovered by electrophoresis.

[0053] The pET-23b plasmid vector was digested with Nde I / EcoRI double enzymes, recovered by agarose electrophoresis and ligated with the target DNA f...

Embodiment 2

[0056] Example 2: Fermentation, purification and detection of interferon α1b163-site serine mutant

[0057] Construct the Escherichia coli engineered bacteria expressing the interferon α1b163 site serine mutant with the same method as in Example 1, then select a single bacterium colony to inoculate in the LB medium containing ampicillin after being activated by coating the plate (per liter uses peptone 10g, yeast powder 5g, NaCl10g, adjust the pH to 7.0), shake the flask at 37°C and 210 rpm to OD 600nm It is 0.6-0.8. Then inoculate 50L LB medium with 5% volume inoculum and carry out fermentation culture in 80L fermenter (containing 0.1% ampicillin per liter). Between -7.5, use the rotating speed to control the dissolved oxygen value between 4-8%. in OD 600nm After reaching 1.0, 10 g of IPTG was added according to the ratio of mass volume ratio 1:5000 to continue the induction culture for 3 hours, the induction culture temperature was 37 ° C, and LB medium was appropriately ...

Embodiment 3

[0063] Example 3: Fermentation, purification and detection of interferon α1b164-site serine mutant

[0064] The Escherichia coli engineered bacteria constructed by the method of Example 1 were activated and shake flask cultured according to the method of Example 2. After inoculating 140L of LB culture in a 200L fermenter with a volume inoculum of 6%, the fermentation culture was carried out, and the conditions were as in Example 2. After the induction culture time is over, put the tank at room temperature and centrifuge at 5000 rpm for 20 minutes to collect the bacteria, and the obtained bacteria are washed twice with the above-mentioned TE buffer to remove the main impurities in the fermentation broth.

[0065] Take 40 g of the thalli obtained from the above-mentioned treatment and add 480 ml of the above-mentioned TE buffer solution at a mass-to-volume ratio of 1:12, and add 4.8 g of lysozyme at a volume-to-mass ratio of 100:1 to treat it for more than 4 hours. Centrifuge f...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biological medicines, and relates to an interferon alpha1b mutant and a fusion protein containing the interferon alpha1b mutant and human serum albumin. The interferon alpha1b mutant is obtained by mutating an arginine from 162-166 bits counting from an N end of an interferon alpha1b amino acid sequence into serine. The interferon alpha1b mutant in the fusion protein containing the interferon alpha1b mutant and the human serum albumin is positioned at an N end of the fusion protein, and the human serum albumin is positioned at a C end of the fusion protein; or the human serum albumin is positioned at the N end of the fusion protein, and the interferon alpha1b mutant is positioned at the C end of the fusion protein. Comparing the interferon alpha1b mutant with an interferon alpha1b and comparing the fusion protein containing the interferon alpha1b mutant and the human serum albumin with a fusion protein containing the interferon alpha1b and the human serum albumin, the interferon alpha1b mutant and the fusion protein containing the interferon alpha1b mutant and the human serum albumin have higher biological activity, better stability and more reliable safety.

Description

technical field [0001] The present invention generally relates to an interferon alpha mutant and its fusion protein, and particularly relates to an interferon alpha 1b mutant and its fusion protein with human serum albumin. Background technique [0002] Interferon (Interferon, IFN) is a kind of cytokine protein drug originally produced by animal organisms with broad-spectrum anti-virus, anti-proliferation and immune regulation effects. According to its production site and mechanism of action, it can be divided into α, β, Large types such as γ and λ, and each large type can be divided into several small subtypes. The difference in the primary structure between different subtypes in the same large type is small, and in the secondary and higher-level structures very close. Among the several major types, the α-type is the most widely used one. Currently, this type of interferon in clinical use mainly includes interferon α2a, interferon α2b, interferon α1b, compound interferon, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K14/56C12N15/21C07K19/00A61K38/21A61K47/48A61P31/12
CPCA61K38/00A61K47/643C07K14/56C07K2319/31
Inventor 刘金毅徐晨周敏毅田硕程永庆
Owner BEIJING TRI PRIME GENE PHARMA CO LTD